• Identified novel drug targets (e.g., [Gene X], [Gene Y]) in lung cancer through network analysis.
• Repurposed FDA-approved drugs (e.g., [Drug A], [Drug B]) showing significant anti-cancer activity.
• Integrated computational and experimental approaches to accelerate drug discovery.
• Provides a roadmap for personalized lung cancer therapy based on molecular profiling.